PGEN
Medium convictionPrecigen, Inc.
Healthcare · NASDAQ
$2.4B mkt cap
Brief updated Today
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its
PGEN driven by gene therapy growth
Precigen, Inc. is a gene and cellular therapy company with 1633.9% year-over-year revenue growth. The company's medium conviction score of 52/100 reflects uncertainty despite a strong buy consensus rating from analysts. With a negative net margin of -64699.0%, the company's financials are under pressure. The macro environment is complex, with US-China tensions potentially impacting the broader healthcare sector.
Why now
The current macro context, including China's chip tool push and the US-China squeeze, makes Precigen's growth prospects compelling. The company's recent revenue growth and buy consensus rating warrant attention, particularly given the 43-year low in US oil reserves amidst Middle East turmoil.
Key risks
Valuation risk is high due to the company's negative P/E ratio of -9.6x and negative intrinsic value. Execution risk is also significant, given the company's substantial negative net margin. Competitive risk from established players in the gene therapy space poses an additional threat.
What to watch
Over the next quarter, watch for updates on Precigen's revenue growth and margin expansion to confirm the thesis. Key events, such as upcoming earnings reports and regulatory approvals, will be crucial in assessing the company's ability to execute on its growth strategy.
China's chip tool push shows ASML caught in US-China squeeze
China is accelerating domestic development of semiconductor manufacturing tools, highlighting ASML's position as a key flashpoint in the US-China tech decoupling conflict. This reflects ongoing pressure from US export controls pushing China to self-sufficiency while squeezing Western chip equipment suppliers caught between geopolitical rivals.
6d ago
Trump Criticized Biden for Draining America’s Oil Reserves. They’re Now at a 43-Year Low Amidst a Middle East War.
US Strategic Petroleum Reserve levels have fallen to a 43-year low, reducing the government's capacity to buffer oil price shocks at a time of active Middle East conflict. This structural vulnerability in US energy policy raises concerns about energy security and the ability to respond to supply disruptions.
6d ago
Trump Criticized Biden for Draining America’s Oil Reserves. They’re Now at a 43-Year Low Amidst a Middle East War.
US Strategic Petroleum Reserve levels have fallen to a 43-year low amid an active Middle East conflict, reducing America's buffer capacity against oil supply disruptions. This constrains the US government's ability to intervene in energy markets during a period of elevated geopolitical risk.
6d ago
U.S. Central Command Posts On X "At 5:45 p.m. ET today, Islamic Revolutionary Guard Corps forces launched multiple ballistic missiles from Iran in an attempted surprise attack on U.S. forces based in the Middle East. All Iranian missiles were successfully intercepted. U.S. forces remain vigilant and at a high state of readiness."
Iranian IRGC forces launched a ballistic missile attack on U.S. military positions in the Middle East, which was fully intercepted according to U.S. Central Command. This represents a direct state-on-state military strike against U.S. forces, dramatically escalating regional tensions and raising the risk of broader conflict.
6d ago
Earnings surprises
+33.3%
2026-05
+90.0%
2026-03
-37.5%
2025-11
+21.4%
2025-08
+12.5%
2025-05
Generated Tue, 04 Aug 2026 05:00:27 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.